ARS Pharmaceuticals officer proposes $402K share sale

Prior transactions listed span September 11 to October 30, 2026.

Available on EDGAR 11/09/2026 - 05:15 PM EST Accepted by SEC EDGAR 11/09/2026 - 05:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ARS Pharmaceuticals, Inc. officer Eric Karas reported a proposed sale of 139,588 common shares, with an aggregate market value of $402,362.41 and an approximate sale date of November 9, 2026. The notice also lists earlier sales: 80,000 shares on October 30, 2026; 100,000 on October 19, 2026; 100,000 on October 1, 2026; 100,000 on September 30, 2026; and 14,064 on September 11, 2026.

Key Figures

Proposed shares for sale: 139,588 common shares Aggregate market value: $402,362.41 Shares sold: 80,000 shares +4 more

7 metrics

Proposed shares for sale 139,588 common shares Approximate sale date November 9, 2026

Aggregate market value $402,362.41 Proposed sale

Shares sold 80,000 shares October 30, 2026

Shares sold 100,000 shares October 19, 2026

Shares sold 100,000 shares October 1, 2026

Shares sold 100,000 shares September 30, 2026

Shares sold 14,064 shares September 11, 2026

Key Terms

Stock Option Exercise, Aggregate Market Value, Gross Proceeds

3 terms

Stock Option Exercise financial

"Nature of Acquisition Transaction: Stock Option Exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Aggregate Market Value financial

"Number of Shares or Other Units To Be Sold | Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Gross Proceeds financial

"Date of Sale | Amount of Securities Sold | Gross Proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SPRY shares does Eric Karas propose to sell?

Eric Karas reported a proposed sale of 139,588 common shares at an aggregate market value of $402,362.41, with an approximate sale date of November 9, 2026.

How did Eric Karas acquire the SPRY shares proposed for sale?

Eric Karas acquired 139,588 common shares through a stock option exercise from the issuer on November 9, 2026, with cash listed as the payment method.

What earlier SPRY share sales by Eric Karas are listed?

The listed sales were 80,000 shares for $270,272.00 on October 30, 2026; 100,000 shares for $410,240.00 on October 19, 2026; 100,000 shares for $426,096.77 on October 1, 2026; 100,000 shares for $431,560.00 on September 30, 2026; and 14,064 shares for $69,761.66 on September 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001951287
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARS PHARMACEUTICALS, INC.
SEC File Number	001-39756
Address of Issuer	11682 El Camino Real Suite 300 San Diego CALIFORNIA 92130
Phone	(858) 771-9307
Name of Person for Whose Account the Securities are To Be Sold	ERIC KARAS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	139588	402362.41	100528400	11/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/09/2026	Stock Option Exercise	Issuer			139588	11/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ERIC KARAS 11682 El Camino Real Suite 300 San Diego CA 92130	Common	10/30/2026	80000	270272.00
ERIC KARAS 11682 El Camino Real Suite 300 San Diego CA 92130	Common	10/19/2026	100000	410240.00
ERIC KARAS 11682 El Camino Real Suite 300 San Diego CA 92130	Common	10/01/2026	100000	426096.77
ERIC KARAS 11682 El Camino Real Suite 300 San Diego CA 92130	Common	09/30/2026	100000	431560.00
ERIC KARAS 11682 El Camino Real Suite 300 San Diego CA 92130	Common	09/11/2026	14064	69761.66

144: Remarks and Signature

Remarks
Date of Notice	11/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Karas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)